TrialThe Lancet. Oncology2015

Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.

Ching-Hon Pui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.